Novocure long-term EF-14 trial data consistent with interim report

Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data.
The trial was designed to assess the Optune/temozolomide combination’s ability to treat glioblastoma that has been newly diagnosed.
“The analysis of the full dataset confirms the improvement in both progression free and overall survival we saw in the trial’s interim analysis, and demonstrates superior long-term survival,” Stupp said. “These mature results further validate Optune as a standard of care treatment option for glioblastoma, providing patients with a therapy that can extend their survival while maintaining their quality of life.”
The interim data analysis for the trial was published in the December 2015 issue of the Journal of the American Medical Association.
“We are excited that Novocure’s long-term analysis of the EF-14 trial confirms the interim analysis results of superior overall and progression free survival, while providing new data on potential long-term survival benefits for newly diagnosed GBM patients,” American Brain Tumor Association President and CEO Elizabeth Wilson said. “GBM patients need better treatment options, and it is a great day when new evidence shows that we are making progress in treating this disease.”